|  | Saline group n = 30 mean ± SD | L-GF group n = 30 mean ± SD | t2 | p2 |
---|---|---|---|---|---|
VAS | Baseline | 7.67 ± 1.92 | 6.90 ± 1.83 | 1.586 | 0.118 |
Follow-up | 5.87 ± 2.60 | 3.97 ± 2.57 | 2.851 | 0.006* | |
t1 | 3.949 | 7.478 | Â | Â | |
p1 |  < 0.001* | < 0.001* |  |  | |
% Change | 1.80 ± 2.50 | 2.93 ± 2.15 | − 1.884 | 0.065 | |
SPADI-pain (%) | Baseline | 69.37 ± 17.19 | 60.03 ± 16.75 | 2.130 | 0.037* |
Follow-up | 55.95 ± 27.02 | 39.20 ± 24.26 | 2.527 | 0.014* | |
t1 | 2.843 | 4.851 | Â | Â | |
p1 | 0.008* |  < 0.001* |  |  | |
% Change | 13.42 ± 25.85 | 20.83 ± 23.52 | − 1.162 | 0.250 | |
SPADI-Disability (%) | Baseline | 56.40 ± 19.35 | 47.73 ± 19.96 | 1.708 | 0.093 |
Follow-up | 48.50 ± 25.58 | 28.67 ± 20.52 | 3.312 | 0.002* | |
t1 | 1.819 | 4.565 | Â | Â | |
p1 | 0.079 |  < 0.001* |  |  | |
% Change | 7.90 ± 23.77 | 19.05 ± 22.86 | − 1.853 | 0.069 | |
SPADI-total (%) | Baseline | 61.28 ± 16.76 | 52.63 ± 16.65 | 2.006 | 0.050* |
Follow-up | 51.36 ± 24.92 | 32.87 ± 20.61 | 3.132 | 0.003* | |
t1 | 2.356 | 5.084 | Â | Â | |
p1 | 0.025* |  < 0.001* |  |  | |
% Change | 9.27 ± 23.76 | 19.88 ± 21.09 | -1.829 | 0.073 |